Robert Califf Offers ‘A Few Words In Favor Of The Tortoise’ When Conducting Clinical Trials
Executive Summary
The once and likely future FDA commissioner emphasizes value of randomized controlled trials, the fact that not all trials are good for people, and how decentralization and digitization are leaving people behind. Takeda exec questions if industry is being bold enough.
You may also be interested in...
Califf Outlines Clinical Trial Reform Message, Which Could Travel With Him To Commissioner’s Office
US FDA commissioner-nominee Califf calls for streamlining clinical trial bureaucracy, as well as open access to clinical data.
What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate
Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.
What Might Have Been: US FDA’s Woodcock Testifies In Senate
Acting US FDA Commissioner Woodcock’s latest appearance before the Senate Health Committee shows once again that she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.